Markova, S M <br/><br/>
Association of CYP2C9*2 with bosentan-induced liver injury.  [electronic resource] 

 -  Clinical pharmacology and therapeutics  Dec 2013 
 - 678-86 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-6535 
<br/><br/><label>Standard No.: </label>10.1038/clpt.2013.143  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alanine Transaminase--metabolism<br/>Aryl Hydrocarbon Hydroxylases--genetics<br/>Aspartate Aminotransferases--metabolism<br/>Bosentan<br/>Chemical and Drug Induced Liver Injury--enzymology<br/>Cytochrome P-450 CYP2C9<br/>Endothelin Receptor Antagonists<br/>Female<br/>Genetic Association Studies<br/>Genetic Markers<br/>HEK293 Cells<br/>Humans<br/>Hypertension, Pulmonary--drug therapy<br/>Liver-Specific Organic Anion Transporter 1<br/>Male<br/>Middle Aged<br/>Multidrug Resistance-Associated Protein 2<br/>Organic Anion Transporters--genetics<br/>Polymorphism, Single Nucleotide<br/>Sulfonamides--adverse effects